Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm Licenses RNAi Technology from MIT

NEW YORK (GenomeWeb News) – Intradigm Corporation has licensed rights to a nucleic acid delivery patent from the Massachusetts Institute of Technology for use in RNAi drug development.
 
The Palo Alto-based company said the IP it has licensed covers a broad range of biodegradable polymer structures that are used in delivering RNAi-based therapeutics. It added that the license would enable it to pursue applications for its NanoPlex technology across a broader range of therapeutic indications.
 
Intradigm’s RNAi Nanoplex technology is made of an active siRNA molecule and a biodegradable polycationic polymer.
 
The company said it will use the licensed technology to “identify, develop, and commercialize optimal delivery platforms.”
 
 Financial terms of the agreement were not released.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.